Literature DB >> 8675668

Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate.

C P Genain1, M H Nguyen, N L Letvin, R Pearl, R L Davis, M Adelman, M B Lees, C Linington, S L Hauser.   

Abstract

In the human disease multiple sclerosis (MS), the immune mechanisms responsible for selective destruction of central nervous system myelin are unknown. In the common marmoset Callithrix jacchus, a unique demyelinating form of experimental allergic encephalomyelitis resembling MS can be induced by immunization with whole myelin. Here we show that the MS-like lesion can be reproduced by immunization against the extracellular domain of a single myelin protein, myelin/oligodendrocyte glycoprotein (MOG). By contrast, immunization against the quantitatively major myelin proteins myelin basic protein or proteolipid protein results in inflammation but little or no demyelination. Furthermore, in the presence of encephalitogenic (e.g., disease-inducing) T cells, the fully demyelinated lesion is reconstructed by systemic administration of IgG purified from whole myelin-, or MOG-immunized animals, and equally by a monoclonal antibody against MOG, but not by control IgG. Encephalitogenic T cells may contribute to the MS-like lesion through disruption of the blood-brain barrier that permits access of demyelinating antibody into the nervous system. The identification of MOG as a major target antigen for autoimmune demyelination in a nonhuman primate should facilitate development of specific immunotherapies for human MS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8675668      PMCID: PMC186008          DOI: 10.1172/JCI118368

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  T-lymphocyte entry into the central nervous system.

Authors:  W F Hickey; B L Hsu; H Kimura
Journal:  J Neurosci Res       Date:  1991-02       Impact factor: 4.164

2.  The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement.

Authors:  S J Piddlesden; H Lassmann; F Zimprich; B P Morgan; C Linington
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

3.  Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats.

Authors:  C Brunner; H Lassmann; T V Waehneldt; J M Matthieu; C Linington
Journal:  J Neurochem       Date:  1989-01       Impact factor: 5.372

4.  Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement.

Authors:  N J Scolding; B P Morgan; W A Houston; C Linington; A K Campbell; D A Compston
Journal:  Nature       Date:  1989-06-22       Impact factor: 49.962

5.  A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease.

Authors:  H J Schluesener; R A Sobel; C Linington; H L Weiner
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

6.  The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.

Authors:  N Sommer; P A Löschmann; G H Northoff; M Weller; A Steinbrecher; J P Steinbach; R Lichtenfels; R Meyermann; A Riethmüller; A Fontana
Journal:  Nat Med       Date:  1995-03       Impact factor: 53.440

7.  Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.

Authors:  C P Genain; T Roberts; R L Davis; M H Nguyen; A Uccelli; D Faulds; Y Li; J Hedgpeth; S L Hauser
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

8.  Experimental autoimmune encephalomyelitis. Augmentation of demyelination by different myelin lipids.

Authors:  G R Moore; U Traugott; M Farooq; W T Norton; C S Raine
Journal:  Lab Invest       Date:  1984-10       Impact factor: 5.662

9.  Identification of a second T cell epitope of human proteolipid protein (residues 89-106) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients.

Authors:  C M Pelfrey; J L Trotter; L R Tranquill; H F McFarland
Journal:  J Neuroimmunol       Date:  1994-09       Impact factor: 3.478

Review 10.  Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review.

Authors:  V K Tuohy
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

View more
  70 in total

Review 1.  Therapeutic strategies in multiple sclerosis. I. Immunotherapy.

Authors:  R Hohlfeld
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

Review 2.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

3.  Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Maria V Tejada-Simon; Jian Hong; Victor M Rivera; Jingwu Z Zhang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 4.  Statins as potential therapeutic agents in multiple sclerosis.

Authors:  Olaf Stüve; Thomas Prod'homme; Sawsan Youssef; Shannon Dunn; Oliver Neuhaus; Martin Weber; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

Review 5.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

Review 6.  Role of microglia in multiple sclerosis.

Authors:  Xinqing Deng; Subramaniam Sriram
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

Review 7.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

8.  Limited sufficiency of antigen presentation by dendritic cells in models of central nervous system autoimmunity.

Authors:  Gregory F Wu; Kenneth S Shindler; Eric J Allenspach; Tom L Stephen; Hannah L Thomas; Robert J Mikesell; Anne H Cross; Terri M Laufer
Journal:  J Autoimmun       Date:  2010-11-20       Impact factor: 7.094

Review 9.  T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.

Authors:  Itay Raphael; Saisha Nalawade; Todd N Eagar; Thomas G Forsthuber
Journal:  Cytokine       Date:  2014-10-30       Impact factor: 3.861

Review 10.  The Charcot Lecture | beating MS: a story of B cells, with twists and turns.

Authors:  Stephen L Hauser
Journal:  Mult Scler       Date:  2014-12-05       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.